~~<i id='2758B2A39B'><strike id='2758B2A39B'><tt id='2758B2A39B'><pre id='2758B2A39B'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：Wikipedia 2025-10-02 06:18:46 Page View：1119

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Innovation in antibiotics is ailing. 'Brain drain' may kill it
Next article： The high cost of giving birth even with insurance

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

FDA panel issues narrow recommendation for Covid vaccine booster doses

ROBYNBECK/AFPviaGettyImagesForanarchivedversionoflivecoverageofthehearingoftheFDA’sadvisorypanel,cli

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Why failed clinical trials don’t always spell doom for a new drug

AdobeThisarticlewasadaptedfromSTAT’slatestreport,“Failedtrial,successfuldrug:howanegativereadoutcans